Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deal Watch: Teva/Mylan/Perrigo Speculation Pushes Busy Celgene, AstraZeneca Offstage

Executive Summary

AstraZeneca and its large-molecule affiliate MedImmune will partner with Celgene to develop anti-PD-LI immune checkpoint inhibitor MEDI4736. MedImmune also signed combination trial agreements with Juno and Immunocore, while Celgene arranged to buy Quanticel and Mesoblast.

You may also be interested in...

Novartis Ups The Ante In Immunotherapy With CoStim Buy

The European pharma is increasing its stake in cancer immunotherapy with the acquisition of a start-up biotech that brings over late-stage assets against several targets.

Array Strikes New Deal For Cancer Drug With Longtime Partner Genentech, Taking $28M Upfront

Genentech gains a second compound that regulates cell cycle progression and Array receives cash to advance four in-house drugs through the clinic.

Seagen CEO Search Under Way As Longtime Leader Siegall Resigns In Scandal

Chief medical officer Roger Dansey has stepped in as interim CEO until a new one is appointed.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts